Gennaro Galizia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5696496/publications.pdf

Version: 2024-02-01

94433 102487 4,551 89 37 66 citations h-index g-index papers 91 91 91 6329 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Prediction of SARS-CoV-2-Related Lung Inflammation Spreading by V:ERITAS (Vanvitelli Early) Tj ETQq1 1 0.78431	1.rgBT /Ov	eglock 10 Tf
2	Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry. Cancers, 2022, 14, 2204.	3.7	12
3	Giant retroperitoneal liposarcoma treated with radical conservative surgery: A case report and review of literature. World Journal of Clinical Cases, 2022, 10, 6636-6646.	0.8	0
4	Naples Prognostic Score Predicts Tumor Regression Grade in Resectable Gastric Cancer Treated with Preoperative Chemotherapy. Cancers, 2021, 13, 4676.	3.7	11
5	Comparison Between Multidetector CT and High–Field 3T MR Imaging in Diagnostic and Tumour Extension Evaluation of Patients with Cholangiocarcinoma. Journal of Gastrointestinal Cancer, 2020, 51, 534-544.	1.3	7
6	Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report. Frontiers in Oncology, 2020, 10, 130.	2.8	4
7	Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer. High-Throughput, 2020, 9, 4.	4.4	1
8	The Role of Near-Infrared Fluorescence Imaging in the Assessment of Peritoneal Carcinomatosis from Colorectal Cancer., 2020, , 183-194.		0
9	Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience. Oncology Letters, 2019, 18, 3873-3879.	1.8	15
10	Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients. Journal of Gastrointestinal Oncology, 2019, 10, 314-323.	1.4	3
11	Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers, 2019, 11, 399.	3.7	46
12	Inflammatory and nutritional status is a predictor of long-term outcome in patients undergoing surgery for gastric cancer. Validation of the Naples prognostic score. Annali Italiani Di Chirurgia, 2019, 90, 404-416.	0.1	8
13	Indocyanine Green Fluorescence Imaging-Guided Surgery in Primary and Metastatic Liver Tumors. Surgical Innovation, 2018, 25, 62-68.	0.9	41
14	Fluorescenceâ€Guided Surgery in the Combined Treatment of Peritoneal Carcinomatosis from Colorectal Cancer: Preliminary Results and Considerations. World Journal of Surgery, 2018, 42, 1154-1160.	1.6	39
15	What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. International Journal of Molecular Sciences, 2018, 19, 2659.	4.1	41
16	Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy. Future Oncology, 2018, 14, 2493-2505.	2.4	15
17	Sigmoid metastasis from endometrioid cancer. Minerva Surgery, 2018, 73, 447-449.	0.6	1
18	Propensity score-matched comparison between complete mesocolic excision and classic right hemicolectomy for colon cancer. Minerva Surgery, 2018, 73, 1-12.	0.6	5

#	Article	IF	CITATIONS
19	Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery. Journal of Gastrointestinal Surgery, 2017, 21, 1764-1774.	1.7	49
20	Naples Prognostic Score, Based on Nutritional and Inflammatory Status, is an Independent Predictor of Long-term Outcome in Patients Undergoing Surgery for Colorectal Cancer. Diseases of the Colon and Rectum, 2017, 60, 1273-1284.	1.3	100
21	Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience. PLoS ONE, 2017, 12, e0173619.	2.5	16
22	Does Preoperative Neutrophil to Lymphocyte Ratio Predict Disease-Free Survival Rate in Colorectal Cancer Patients Undergoing Curative Surgery?. Annals of Surgery, 2016, 263, e80.	4.2	0
23	NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer, 2016, 16, 709.	2.6	48
24	Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. ESMO Open, 2016, 1, e000038.	4.5	66
25	Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis. Surgery, 2015, 157, 285-296.	1.9	49
26	CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence. Oncology Letters, 2015, 9, 542-550.	1.8	18
27	Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis. Surgery, 2015, 158, 112-120.	1.9	71
28	Reply "Modified D2 lymphadenectomy is effective in patients with node-positive gastric cancers undergoing potentially curative total gastrectomy― Surgery, 2015, 158, 1447-1448.	1.9	1
29	Treatment of esophagogastric junction carcinoma: An unsolved debate. World Journal of Gastroenterology, 2015, 21, 4427-4431.	3.3	4
30	Treatment of gastric cancer. World Journal of Gastroenterology, 2014, 20, 1635.	3.3	508
31	Effect of Preoperative Chemoradiotherapy on Outcome of Patients with Locally Advanced Esophagogastric Junction Adenocarcinoma—A Pilot Study. Current Oncology, 2014, 21, 125-133.	2.2	13
32	Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study. International Journal of Colorectal Disease, 2014, 29, 89-97.	2.2	107
33	Clinical management of advanced gastric cancer: The role of new molecular drugs. World Journal of Gastroenterology, 2014, 20, 14537.	3.3	41
34	Postoperative Detection of Circulating Tumor Cells Predicts Tumor Recurrence in Colorectal Cancer Patients. Journal of Gastrointestinal Surgery, 2013, 17, 1809-1818.	1.7	45
35	CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo. Cancer, 2013, 119, 729-738.	4.1	57
36	Preoperative treatment of locally advanced esophageal carcinoma. International Journal of Oncology, 2013, 43, 1745-1753.	3.3	8

#	Article	IF	CITATIONS
37	Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. Oncology Reports, 2013, 30, 2992-2998.	2.6	11
38	Radiofrequency-Assisted Liver Resection With a Comb-Shaped Bipolar Device Versus Clamp Crushing. Surgical Innovation, 2012, 19, 407-414.	0.9	6
39	Combined CD133/CD44 Expression as a Prognostic Indicator of Disease-Free Survival in Patients With Colorectal Cancer. Archives of Surgery, 2012, 147, 18.	2.2	68
40	Current status of targeted therapies in advanced gastric cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S29-S34.	3.4	35
41	The Over-The-Scope-Clip (OTSC) System is Effective in the Treatment of Chronic Esophagojejunal Anastomotic Leakage. Journal of Gastrointestinal Surgery, 2012, 16, 1585-1589.	1.7	35
42	Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials. Ecological Management and Restoration, 2012, 25, 130-136.	0.4	20
43	A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. British Journal of Cancer, 2011, 104, 427-432.	6.4	42
44	Behavior of Circulating CD4+CD25+Foxp3+ Regulatory T Cells in Colon Cancer Patients Undergoing Surgery. Journal of Clinical Immunology, 2011, 31, 1095-1104.	3.8	38
45	Endoscopic Intraoperative Anastomotic Testing May Avoid Early Gastrointestinal Anastomotic Complications. A Prospective Study. Journal of Gastrointestinal Surgery, 2011, 15, 145-152.	1.7	25
46	A subtle case of iron-deficiency anemia. Internal and Emergency Medicine, 2011, 6, 191-192.	2.0	0
47	Dufourmentel Rhomboid Flap in the Radical Treatment of Primary and Recurrent Sacrococcygeal Pilonidal Disease. Diseases of the Colon and Rectum, 2010, 53, 1061-1068.	1.3	31
48	Adjuvant Chemoradiotherapy in Patients With Stage III or IV Radically Resected Gastric Cancer. Archives of Surgery, 2010, 145, 233.	2.2	17
49	Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study. Cancer Investigation, 2010, 28, 820-827.	1.3	18
50	Perspectives in Adjuvant Therapy of Gastric Cancer. Oncology, 2009, 77, 38-42.	1.9	17
51	The Lymph Node Ratio Is a Powerful Prognostic Factor of Nodeâ€Positive Colon Cancers Undergoing Potentially Curative Surgery. World Journal of Surgery, 2009, 33, 2704-2713.	1.6	38
52	Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: A single institution retrospective analysis. Oncology Reports, 2009, 21, 1023-8.	2.6	48
53	Prognostic Biomarkers and Targeted Therapy in Gastric Cancer: Reply. World Journal of Surgery, 2008, 32, 1227-1229.	1.6	6
54	Complete pathological response of colorectal liver metastases after chemotherapy and bevacizumab treatment: a case report. Targeted Oncology, 2008, 3, 253-258.	3.6	2

#	Article	IF	CITATIONS
55	Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients. Annals of Surgical Oncology, 2008, 15, 69-79.	1.5	220
56	Integrated Therapy in Localized Gastric Cancer: Targeted and Tailored Approach. Annals of Surgical Oncology, 2008, 15, 2983-2985.	1.5	1
57	First-Line Chemotherapy vs Bowel Tumor Resection Plus Chemotherapy for Patients With Unresectable Synchronous Colorectal Hepatic Metastases. Archives of Surgery, 2008, 143, 352.	2.2	114
58	Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM) Tj ETC)q0 01(12rgB ⁻	「/Owerlock 10
59	Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 242-248.	0.3	0
60	Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass. World Journal of Surgical Oncology, 2007, 5, 42.	1.9	11
61	Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene, 2007, 26, 3654-3660.	5.9	140
62	Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery. World Journal of Surgery, 2007, 31, 1458-1468.	1.6	140
63	Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery. Annals of Surgical Oncology, 2006, 13, 823-835.	1.5	104
64	Feasibility of Primary Inguinal Hernia Repair with a New Mesh. World Journal of Surgery, 2006, 30, 1055-1062.	1.6	3
65	p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. Journal of Surgical Oncology, 2006, 93, 241-252.	1.7	35
66	Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. Annals of Oncology, 2006, 17, 1529-1532.	1.2	14
67	A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. British Journal of Cancer, 2005, 92, 1644-1649.	6.4	171
68	Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: A retrospective comparison of 138 liver resections. British Journal of Surgery, 2005, 76, 871-876.	0.3	2
69	Cetuximab in the treatment of colorectal cancer. Future Oncology, 2005, 1, 173-181.	2.4	17
70	Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas. Clinical Cancer Research, 2004, 10, 3490-3499.	7.0	103
71	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3089-3094.	7.1	175
72	Prognostic Value of p27, p53, and Vascular Endothelial Growth Factor in Dukes A and B Colon Cancer Patients Undergoing Potentially Curative Surgery. Diseases of the Colon and Rectum, 2004, 47, 1904-1914.	1.3	30

#	Article	IF	Citations
73	Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer, 2004, 100, 270-278.	4.1	100
74	Normal Interleukin-10 Serum Level Opposed to High Serum Levels of Carbohydrate Antigen 19-9 and Cancer Antigens 125 and 50 in a Case of True Splenic Cyst. Archives of Medical Research, 2003, 34, 145-148.	3.3	12
75	A True Splenic Cyst Producing Carbohydrate Antigen 19-9 and Cancer Antigens 50 and 125, but Not Interleukin 10. Digestive Surgery, 2003, 20, 71-74.	1.2	7
76	Elevated Serum Levels of Interleukin-8 in Advanced Non-Small Cell Lung Cancer Patients: Relationship with Prognosis. Journal of Interferon and Cytokine Research, 2002, 22, 1129-1135.	1.2	70
77	Preoperative Chemoradiotherapy for Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus. Chest, 2002, 122, 1302-1308.	0.8	52
78	Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet, The, 2002, 359, 219-225.	13.7	140
79	Prognostic Significance of Circulating IL-10 and IL-6 Serum Levels in Colon Cancer Patients Undergoing Surgery. Clinical Immunology, 2002, 102, 169-178.	3.2	196
80	Circulating Levels of Interleukin-10 and Interleukin-6 in Gastric and Colon Cancer Patients Before and After Surgery: Relationship with Radicality and Outcome. Journal of Interferon and Cytokine Research, 2002, 22, 473-482.	1.2	60
81	Hemodynamic and pulmonary changes during open, carbon dioxide pneumoperitoneum, and abdominal wall-lifting cholecystectomy. Surgical Endoscopy and Other Interventional Techniques, 2001, 15, 477-483.	2.4	148
82	Counting alleles reveals a connection between chromosome 18q loss and vascular invasion. Nature Biotechnology, 2001, 19, 78-81.	17. 5	59
83	Interleukin-6 Serum Level Correlates with Survival in Advanced Gastrointestinal Cancer Patients but Is Not an Independent Prognostic Indicator. Journal of Interferon and Cytokine Research, 2001, 21, 45-52.	1.2	76
84	Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunology, Immunotherapy, 2000, 49, 530-536.	4.2	51
85	Serum Interleukin-10 Levels as a Prognostic Factor in Advanced Non-small Cell Lung Cancer Patients. Chest, 2000, 117, 365-373.	0.8	139
86	Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. , 1999, 86, 1936-1943.		75
87	Intraoperative ultrasonography in resection of small hepatocellular carcinoma associated with cirrhosis. American Journal of Surgery, 1989, 158, 40-42.	1.8	22
88	Androgen Receptor in Hepatocellular Carcinoma as a Prognostic Factor After Hepatic Resection. Annals of Surgery, 1989, 209, 424-427.	4.2	50
89	EVIDENCE THAT CYCLOSPORINE PRETREATMENT PROTECTS LYSOSOMAL MEMBRANE IN LIVER ISCHEMIA IN DOGS. Transplantation, 1989, 47, 924-926.	1.0	10